Sana Biotechnology
SANA
203 hedge funds and large institutions have $473M invested in Sana Biotechnology in 2026 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 69 increasing their positions, 56 reducing their positions, and 25 closing their positions.
275% more call options, than puts
Call options by funds: $2.17M | Put options by funds: $577K
23% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 56
20% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 25
1.76% more ownership
Funds ownership: 59.78% → 61.54% (+1.8%)
0% more funds holding
Funds holding: 203 → 203 (0)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
27% less capital invested
Capital invested by funds: $649M → $473M (-$176M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$9.78M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$6.93M |
| 3 |
Goldman Sachs
New York
|
+$6.67M |
| 4 |
Millennium Management
New York
|
+$3.81M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$2.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$2.85M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$2.54M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.2M |
| 4 |
Jane Street
New York
|
-$2.11M |
| 5 |
Barclays
London,
United Kingdom
|
-$1.88M |
SANA Hedge Fund Activity: Q1 2026 in Review
203 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Sana Biotechnology (SANA) for Q1 2026, worth a combined $473M — down 27% from $649M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new SANA positions and 25 closed out — a net gain of 5 holders — while 69 added to existing stakes and 56 trimmed.
The largest buyer was State Street, adding an estimated $9.78M. The largest seller was Great Point Partners, exiting entirely with an estimated $2.85M sold.
- 203 institutional investors held Sana Biotechnology (SANA) as of Q1 2026, unchanged from Q4 2025.
- Funds reported $473M of Sana Biotechnology stock for Q1 2026, down 27% quarter-over-quarter.
- 30 funds opened new Sana Biotechnology positions in Q1 2026 and 25 closed out, a net change of +5 holders.
- The largest Sana Biotechnology buyer in Q1 2026 was State Street, an estimated $9.78M added.
- The largest Sana Biotechnology seller in Q1 2026 was Great Point Partners, an estimated $2.85M sold.
Based on aggregated 13F filings for Q1 2026.